Thurston Springer Miller Herd & Titak Inc. Buys 7,661 Shares of Medtronic PLC $MDT

04 Apr 2026, 12:34 by Mitch Edgeman · The Markets Daily

Thurston Springer Miller Herd & Titak Inc. grew its position in Medtronic PLC (NYSE:MDT – Free Report) by 400.7% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 9,573 shares of the medical technology company’s stock after purchasing an additional 7,661 shares during the period. Thurston Springer Miller Herd & Titak Inc.’s holdings in Medtronic were worth $920,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. State Street Corp lifted its holdings in Medtronic by 1.0% during the 3rd quarter. State Street Corp now owns 60,460,537 shares of the medical technology company’s stock valued at $5,800,550,000 after purchasing an additional 625,992 shares during the last quarter. Bank of New York Mellon Corp grew its stake in Medtronic by 0.9% during the third quarter. Bank of New York Mellon Corp now owns 21,468,260 shares of the medical technology company’s stock worth $2,044,637,000 after buying an additional 192,410 shares during the last quarter. Massachusetts Financial Services Co. MA grew its stake in Medtronic by 0.5% during the third quarter. Massachusetts Financial Services Co. MA now owns 21,086,499 shares of the medical technology company’s stock worth $2,008,278,000 after buying an additional 98,220 shares during the last quarter. Raymond James Financial Inc. increased its holdings in shares of Medtronic by 3.0% during the third quarter. Raymond James Financial Inc. now owns 11,203,865 shares of the medical technology company’s stock worth $1,067,055,000 after buying an additional 327,899 shares in the last quarter. Finally, Wellington Management Group LLP increased its holdings in shares of Medtronic by 35.3% during the third quarter. Wellington Management Group LLP now owns 10,189,586 shares of the medical technology company’s stock worth $970,456,000 after buying an additional 2,658,981 shares in the last quarter. Institutional investors own 82.06% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on MDT. Citigroup assumed coverage on Medtronic in a report on Tuesday, February 3rd. They issued a “buy” rating and a $117.00 target price on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $120.00 price target on shares of Medtronic in a report on Thursday, March 26th. Sanford C. Bernstein lifted their price objective on Medtronic from $111.00 to $112.00 and gave the company an “outperform” rating in a research report on Friday, January 9th. Daiwa Securities Group reduced their price objective on Medtronic from $117.00 to $115.00 and set a “buy” rating on the stock in a research note on Friday, February 27th. Finally, Truist Financial decreased their target price on Medtronic from $107.00 to $103.00 and set a “hold” rating on the stock in a report on Wednesday, February 18th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat, Medtronic presently has an average rating of “Moderate Buy” and a consensus price target of $109.85.

View Our Latest Research Report on MDT

Insider Activity at Medtronic

In related news, EVP Harry Skip Kiil sold 52,524 shares of Medtronic stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the completion of the sale, the executive vice president directly owned 32,768 shares of the company’s stock, valued at $3,201,761.28. The trade was a 61.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.26% of the stock is currently owned by company insiders.

Medtronic Stock Down 0.0%

NYSE MDT opened at $86.61 on Friday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54. Medtronic PLC has a 52 week low of $79.55 and a 52 week high of $106.33. The stock has a market capitalization of $111.19 billion, a P/E ratio of 24.12, a price-to-earnings-growth ratio of 2.24 and a beta of 0.75. The stock has a fifty day moving average of $94.47 and a 200-day moving average of $96.22.

Medtronic (NYSE:MDT – Get Free Report) last posted its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.34 by $0.02. The business had revenue of $9.02 billion for the quarter, compared to analysts’ expectations of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The firm’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter last year, the business earned $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, equities research analysts forecast that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, April 17th. Stockholders of record on Friday, March 27th will be given a $0.71 dividend. This represents a $2.84 annualized dividend and a dividend yield of 3.3%. The ex-dividend date is Friday, March 27th. Medtronic’s dividend payout ratio (DPR) is currently 79.11%.

About Medtronic

(Free Report)

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.